Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient

• Main Authors: Zhuo Zhang, Ling Xu, Naishan Qin, Jixin Zhang, Qian Xiang, Qian Liu, Yuanjia Cheng, Yuge Bai, Qianxin Liu, Yinhua Liu, Xuening Duan, Yimin Cui
• Format: Article
• Language: English
• Published: Wiley 2021-06-01
• Series: Thoracic Cancer
• Subjects: case report; cholestatic drug‐induced liver injury; lapatinib; secondary sclerosing cholangitis; vinorelbine
• Online Access: https://doi.org/10.1111/1759-7714.13986
• ISSN: 1759-7706; 1759-7714

Abstract Secondary sclerosing cholangitis (SSC) is a rare cholestatic liver disease that may have a severe clinical course. A 61‐year‐old woman with a history of metastasis breast cancer was admitted to our hospital for the second cycle of chemotherapy with lapatinib and vinorelbine. The patient had no reports of elevated liver function tests (LFTs) in the previous multiple chemotherapies or history of liver disease. However, the admission laboratory results showed severe cholestatic liver injury with the possibility of SSC by magnetic resonance cholangiopancreatography. Although chemotherapy was discontinued and patient was treated with hepatoprotective drugs, the LFTs did not improve and liver biopsy indicated mild injury of intrahepatic bile duct epithelium and hepatocyte. We added ursodeoxycholic acid and prednisolone to protect the liver, and laboratory data showed a response. To prevent the progression, lapatinib and vinorelbine were reintroduced and transient increases in alanine aminotransferase and γ‐glutamyl transpeptidase were observed. With no evidence of viral or autoimmune liver disease, SSC induced by lapatinib and vinorelbine was diagnosed. This is the first case report of tyrosine kinase inhibitors and vinorelbine induced SSC and clinicians should be aware of the possibility of it. More case reports about this adverse drug reaction are needed to delineate optimal management.